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Static light scatteringThe amyloid precursor protein (APP) and its cellular processing are believed to be centrally involved in
the etiology of Alzheimer’s disease (AD). In addition, many physiological functions have been described
for APP, including a role in cell–cell- and cell–ECM-adhesion as well as in axonal outgrowth. We show
here the molecular determinants of the oligomerization/dimerization of APP, which is central for its
cellular (mis)function. Using size exclusion chromatography (SEC), dynamic light scattering and SEC-
coupled static light scattering we demonstrate that the dimerization of APP is energetically induced by
a heparin mediated dimerization of the E1 domain, which results in a dimeric interaction of E2. We also
show that the acidic domain (AcD) interferes with the dimerization of E1 and propose a model where
both, cis- and trans-dimerization occur dependent on cellular localization and function.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The amyloid precursor protein (APP) is generally regarded as a
key player in the development of Alzheimer’s disease (AD), none-
theless because the neurotoxic, plaque forming Ab-peptide species
are derived from it by sequential cleavage by b- and c-secretase
(reviewed e.g. in Blennow et al., 2006; Lichtenthaler et al., 2011;
Selkoe, 2001; Thinakaran and Koo, 2008). In addition, it appears
together with its mammalian homologues, the APP-like proteins
1 and 2 (APLP1 and APLP2), to be essential for proper neuronal
development and function (Anliker and Muller, 2006; Aydin
et al., 2012) and has been implicated with a function at synaptic
contacts (Baumkotter et al., 2012). APP is a type-I transmembrane
protein exhibiting a large extracellular domain. For the neuron-
speciﬁc splice form APP695, it is divided into the two rigidly folded
E1- and E2-domains that are connected to one another and to its
single transmembrane helix (TM) by the ﬂexible acidic domain
(AcD) and the likewise mostly unstructured juxtamembrane region
(JMR) (Coburger et al., 2013). The longer isoforms of APP addition-
ally include a Kunitz-type protease inhibitor domain (KPI) between
AcD and E2 (Reinhard et al., 2005). Several additional physiological
functions have been described for APP, including its function as an
atypical ligand of DR6 (Kuester et al., 2011; Nikolaev et al., 2009);
as a receptor (Ho and Sudhof, 2004); as a cell–cell- and cell–ECM–
adhesion molecule (Breen et al., 1991; Soba et al., 2005); and as aprotein for metal binding and transport (Bush et al., 1993; Duce
et al., 2010; Hesse et al., 1994; Honarmand Ebrahimi et al.,
2013). Recently, a novel metal binding site was described to reside
within the E2 domain (Dahms et al., 2012), which is different from
the widely discussed metal-binding site within the CuBD of E1
(Kong et al., 2007) and seems to act as conformational switch
regulating the metal-dependent properties of APP.
Interestingly, dimerization of the protein was shown to inﬂu-
ence a wide range of the above described physiological functions
of APP but also its proteolytic processing central to AD. One central
question regarding the structure–function-relationship of APP is
thus, which parts of this multi-domain-protein are responsible
for multimerization and how such an interaction affects its
physiological and pathological properties. First hints towards a
dimerization and their effect on the proteolytic processing of APP
were observed more than a decade ago (Scheuermann et al.,
2001). In addition, the formation of homo- and heterodimers of
the APP-family proteins has been shown to affect e.g. cell–cell-
adhesion (Soba et al., 2005) and its proteolytic processing
(Munter et al., 2007). Dimerization sites have been reported to
be located at the positively charged loop encompassing cysteines
98 and 105 of the E1 domain (Dahms et al., 2010; Kaden et al.,
2008), within the E2 domain (Lee et al., 2011; Wang and Ha,
2004; Xue et al., 2011) and within the transmembrane segment
of APP (Munter et al., 2007; Nadezhdin et al., 2012). In addition,
dimerization was reported to require the interaction of the entire
ectodomain with long heparin sulfates (Gralle et al., 2006). Also
cis- and trans-dimerization of cell-bound APP has been shown
(a) (b)
(c)
Fig.1. Overall structure of APP, used constructs and E1-dimer. (a) The APP-ectodomain consists of the two folded subdomains, E1 (itself consisting of the GFLD and the CuBD)
and E2 that are connected to one another and to the membrane (TM) by the ﬂexible segments AcD and JMR. Used constructs of the APP-ectodomain are indicated by double-
headed arrows. (b) Dimeric arrangement of two E1-molecules as found in the crystal (PDB: 3ktm) (Dahms et al., 2010). Molecule B is illustrated in cartoon representation,
molecule D in a surface representation and the modelled heparin chain is shown in stick representation. The two mutated lysine residues are shown as spheres for molecule B.
This panel was prepared with PyMOL (http://www.pymol.org). (c) Analytical SEC of wtAPP-E1 and of its K103/106E double mutant in the absence (blue) and presence (red) of
short chain heparin.
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the binding of heparin chains of various lengths to different APP-
segments and their inﬂuence on dimerization has been described
(Dahms et al., 2010; Gralle et al., 2006; Lee et al., 2011). It is,
however, unclear, which of the described contacts form with high
afﬁnity (low KD) also at low protein concentration and which con-
tacts correspond to low afﬁnity and hence are probably the conse-
quence of other interactions that energetically must occur
beforehand. The two structurally well-deﬁned regions E1 and E2
are predestined to represent sites of such high-afﬁnity dimeriza-
tion. An initial dimerization at the single transmembrane helix of
APP is unlikely to be the physiologically primary driving force, as
also evidenced by a competing binding of this region to cholesterol
(Song et al., 2013) and the fact that mutations in this segment do
not affect the oligomerization of APP (So et al., 2013).
In order to understand the oligomerization of APP on the molec-
ular level, we created mutations within the previously identiﬁed
dimerization site of APP-E1 and characterized heparin binding as
well as APP-dimerization by E1 and E2 employing different APP
constructs (Fig. 1a). In addition, we also investigated the effect of
the region between E1 and E2 on the dimerization of APP, allowing
us to reﬁne the understanding of APP-mediated dimerization.2. Materials and methods
2.1. Cloning, protein expression and purification
APP, its constructs and its mutant form were expressed and
puriﬁed as described before (Coburger et al., 2013; Dahms et al.,
2010; Honarmand Ebrahimi et al., 2013). The double mutant of
E1 was generated from the E1 wt clone (Dahms et al., 2010) by
QuikChange site directed mutagenesis (Stratagene) employing a
primer pair corresponding to the following sequence:50-GGTGCAAGCGGGGCCGCGAACAGTGCGAAACCCATCCCCACTT
TGTG-30
Success of the mutagenesis was checked by sequencing
(Qiagen).
The APP-ED_AcD_E2 construct comprising E192-D500 (APP695-
numbering) was cloned into pET22b using the following primer
pair, expressed like the E2-domain and puriﬁed using a HisTrap
FF crude (GE Healthcare) and a SD200 10/300 size exclusion col-
umn (GE Healthcare):
 50-AAAAAACATATGGAAGAAAGTGACAATG-30
 50-AAAAAAAAAAAGCTTACGACCTTCGATGTCATCTGAA-
TAGTTTTG-302.2. Heparin binding assay
A 1.2 ml heparin column (heparin Sepharose, GE Healthcare)
was prepared and used on an Aekta Micro system (GE Healthcare)
to bind the different APP variants at 100 mM NaCl, 5 mM tris, pH
8.0. Elution was done with a linear salt gradient up to 1 M NaCl
during 20 column volumes.2.3. Dimerization experiments using analytical SEC
An Aekta Micro system with a calibrated SD 200 5/150 tricorn
column (both GE Healthcare) was used to perform analytical SEC
in the absence and presence of heparin employing a buffer contain-
ing 150 mM NaCl, 5 mM tris, pH 8.0, if necessary supplemented
with 2.5 mM Clivarin (Abbott). Proteins were used at 50 lM and
all runs were done in triplicate.
(a)
(b)
Fig.2. DLS analysis of APP_E1 and APP_E2: DLS-derived apparent MW as function of
the protein concentration ranging from 0.6 to 20 mg/ml for (a) wtAPP-E1 and its
K103/106E double mutant and (b) of APP-E2. The bars represent the mean values of
three independent measurements and the standard deviation is indicated.
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DLS experiments were performed using a DLS 802 instrument
(Viskotek) at different protein concentrations. The measurements
were done in 14 and 45 ll quartz cuvettes (Hellma Analytics) at
protein concentration higher and lower than 2.5 mg/ml, respec-
tively. All data were collected at 20 C with a duration time of
5 s. For the measurements a buffer containing 150 mM NaCl,
5 mM tris, pH 8.0 was used. All measurements were done in tripli-
cates and the evaluation of the data was performed using the
OmniSize software (Viscotek).
2.5. Static light scattering
SLS experiments were done employing a Superdex 200 10/300
SEC column attached to an Aekta Explorer system (both GE Health-
care) coupled to VE3580 RI and 270 Dual detectors (Viscotek).
Evaluation of the data was performed using the OmniSec software
(Viscotek) and the RI signal. For the dimerization experiments of
the APP-E2 domain, the protein concentration was adjusted to
50 lM in 150 mM NaCl, 10 mM Na3PO4 at pH 7.3 complemented
with different heparin preparations (Clivarin, Abott; Lovenox, Kol-
pharma GmbH, heparin-sodium salt sc-203075, Santa Cruz Bio-
technology; heparin-sodium-salt H-3393, Sigma–Aldrich) at
100 lM each. For all SLS measurements with other APP prepara-
tions the otherwise identical buffer was supplemented with
100 lM Clivarin (Abbott). All measurements were done in
triplicate.
2.6. MW determination of used heparin preparations
Analytical SEC was performed with 1 mM of the respective hep-
arin preparation on a SD75 PC 3.2 column attached to an Aekta
Micro system (both GE Healthcare) in a buffer containing
150 mM NaCl, 10 mM Na3PO4, pH 7.3. The column was calibrated
using heparin chains of deﬁned length; dp4, dp8, dp12, dp16 and
dp24 (Dextra Laboratories Ltd). Because of the chemical cleavage
during the preparation of the heparins, they show absorption at
220 nm which was used for analysis. To prove the presence of
the heparins in the respective fractions their heparin content was
also measured using a phenol–sulfuric acid-assay (Saha and
Brewer, 1994).3. Results
3.1. The K103/106 mutation prevents the dimerization of the APP-E1
domain
We previously characterized the site of heparin-dependent
dimerization of APP-E1 by biochemical experiments and protein
crystallography (Dahms et al., 2010). Based on these data, we
designed the K103/106E double mutant (Fig. 1b), which eliminates
several dimer-forming interactions between the two protomers of
the wild type protein and their interaction with the negatively
charged heparin. Re-application of wtAPP-E1 and of this mutant
to analytical size exclusion chromatography (SEC) showed the
expected results: Whereas the apparent molecular weight (MW)
of the wtAPP-E1 increased about twofold upon the addition of
the 4 kDa heparin Clivarin, no such heparin-induced dimerization
was observed for the double mutant (Fig. 1c).
We next asked if the isolated APP-E1 can also dimerize without
the addition of heparin. We therefore analyzed the apparent MW
of both wtAPP-E1 and of its K103/106E double mutant at high pro-
tein concentrations by dynamic light scattering (DLS). At the
slightly basic pH of 8.0, the apparent MW of the wtAPP-E1increased from 29.0 ± 5.0 kDa at 0.6 mg/ml to 68.2 ± 2.9 kDa at
concentrations of 20 mg/ml (Fig. 2a). In contrast, the MW of the
K103/106E double mutant remained basically unchanged over this
concentration range. The small increase of its apparent MW is most
likely due to the increase of viscosity of the protein samples at
higher protein concentrations. This observation also shows that
the observed increase in MW for wtAPP-E1 is due to the dimeriza-
tion of the molecules and arises not only from a higher viscosity of
the samples.3.2. APP-E2 is monomeric in solution and dimerizes at higher protein
concentrations
We next analyzed the oligomerization behavior of APP-E2. First
we analyzed its absolute MW in solution using SEC-coupled static
light scattering and determined it to be 27.0 ± 0.3 kDa, which is in
good agreement with its theoretical MW of 25.6 kDa. This shows
that this domain is monomeric in solution under the employed
conditions, as observed before for APP (Lee et al., 2011) and its
Caenorhabditis elegans homologue APL-1 (Hoopes et al., 2010).
Next, we performed DLS-measurements with APP-E2 at different
protein concentrations similar to those done with APP-E1 in order
to analyze if the E2 domain self-dimerizes in the absence of hepa-
rin at higher protein concentrations (Fig. 2b). Its apparent MW
increased from 41.4 ± 1.1 kDa up to 93.4 ± 6.0 kDa with increasing
concentrations ranging from 0.6 to 20.0 mg/ml APP-E2. This nicely
ﬁts to dimeric MW and shows that not only the E1 but also the E2
domain is able to self-dimerize at high protein concentrations.
Small differences in the measured absolute molecular weight
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molecular weight determined by DLS are most likely caused by the
elongated structure of the E2 domain.3.3. APP-E2 binds heparin but does not dimerize in a heparin-
dependent manner
Prompted by previous analyses of the heparin-dependent
dimerization of APP-E2 (Lee et al., 2011) we investigated in detail,
how heparin chains of different length promote this effect. As E2
binds heparin (Mok et al., 1997), a sufﬁciently long heparin chain
will always independently bind to and hence cross-connect two
E2-moieties, resulting in a functional dimerization. For a heparin-
induced protein–protein dimer, one would expect, however, that
this effect is also seen for short heparin chains that stabilize pre-
existing, weak protein–protein contacts as observed previously
for APP-E1 (Dahms et al., 2010). As the size of the used heparin
preparations is crucial for such an analysis, we experimentally
determined them, employing heparin chains of deﬁned length as
standard (Fig. 3). The typical absorption at 220 nm of the prepara-
tions was hereby used to readily detect their concentration within
the SEC analyses. To further conﬁrm the presence of heparin, the
respective fractions were also analyzed with phenol–sulfuric acid
(Saha and Brewer, 1994). We found that the overall distribution
of the heparin chain length was very broad for all used heparin
preparations. The obtained values corresponded to an apparent
MW of 0.35 kDa per sugar residue, agreed nicely with the givenFig.3. Determination of heparin chain lengths using analytical SEC. The number of
sugar residues is given as function of the retention volume as determined by the
peak of the 220 nm absorption. Five heparin preparations of deﬁned length (dp4,
dp8, dp12, dp16, dp24 (Dextra Laboratories)) were used to calibrate a SD75 PC3.2
column and are shown as asterisk together with the calculated calibration curve.
This calibration was used to determine the chain lengths of the heparin prepara-
tions employed in our dimerization experiments indicated by numbered diamonds
as follows: (1) Clivarin, average MW of 4 kDa, chain length of 11 sugar residues; (2)
Lovenox, 5.2 kDa, 15 residues; (3) sc-203075 (SantaCruz), 15 kDa, 44 residues; (4)
H-3393 (Sigma–Aldrich), 19 kDa, 55 residues).
Table 1
Heparin induced dimerization experiments of APP-E1 and APP-E2.
Sample Theoret. MW
(kDa) of a
monomerb
Absolute MW
determined
by SLS (kDa)
APP-E1a 22 22 ± 0.2
APP-E1 + Clivarin (4 kDa)a 26 42 ± 2.0
APP-E2 26 27 ± 0.3
APP-E2 + Clivarin (4 kDa) 30 32 ± 0.6
APP-E2 + Lovenox (5 kDa) 31 32 ± 0.3
APP-E2 + SantaCruz (15 kDa) 41 48 ± 0.3
APP-E2 + SigmaHP (19 kDa) 45 74 ± 2.2
a Values are taken from Dahms et al. (2010).
b The calculated theoretical values include one bound heparin chain.manufacturer’s values and ranged from 4 kDa or 11 sugar moieties
(Clivarin) to 19 kDa or 55 sugar moieties (H-3393).
Afterwards these heparin preparations of different length were
used for SLS measurements in order to determine the absolute MW
of the respective APP-E2-heparin complexes (Table 1). The addition
of the 4 kDa Clivarin to APP-E2 led, differently from the dimeriza-
tion of APP-E1 (Dahms et al., 2010), only to a small increase of the
absolute MW to 32 ± 0.6 kDa, probably corresponding to mono-
meric protein with one bound heparin molecule. Similar results
were obtained for the addition of the 5 kDa heparin Lovenox to
the protein, which resulted in an absolute MW of 32 ± 0.3 kDa. This
situation changed when we used the two longer heparin prepara-
tions of 15 and 19 kDa. We now observed a larger difference
between the theoretical MW of a monomeric protein with one
bound heparin chain and the measured MWs. The observed value
for the 15 kDa heparin was still too low for a dimer cross-con-
nected by one heparin-chain which would correspond to a theoret-
ical MW of 63 kDa. The best interpretation of the observed
intermediate value is probably the simultaneous presence of
monomeric E2 bound to one heparin chain and two E2-molecules
independently bound to the longer heparin chain. In the case of
the 19 kDa heparin the measured value ﬁts to dimerized protein,
corresponding most likely to two protein molecules independently
bound to the long heparin chain.
3.4. The acidic region interferes with dimerization of the APP-E1
domain
After we analyzed the contributions of the E1 and the E2
domain to the dimerization of APP we additionally performed the
dimerization experiments with a construct comprising the whole
ectodomain of APP (APP-Ecto). Surprisingly, SLS experiments in
the absence and presence of heparin did not show marked differ-
ences in the absolute MW and therefore no heparin induced dimer-
ization (Table 2). To clarify which part of the APP-ectodomain is
responsible for this apparent loss of dimerization potential, we
performed similar experiments with the APP-E1_ED_AcD and the
APP-E1_ED constructs of intermediate length (see Fig. 1a for the
domain organization of APP). As observed for the entire ectodo-
main, our SLS experiments with these two constructs both in the
presence and the absence of the short chain heparin Clivarin indi-
cated binding but no dimerization (Table 2). This shows, that the
section between E1 and E2 (ED_AcD) regulates or interferes with
the heparin induced dimerization of the APP-E1 domain.
3.5. The negatively charged ED_AcD reduces the heparin afﬁnity of E1
We also analyzed how strongly the different constructs bind to
a heparin-column (Fig. 4). The strongest binder is APP-E2, which
eluted at 540 mM NaCl, followed by isolated APP-E1, which
eluted at 450 mM NaCl. The elongated E1-fragments APP_E1_ED
and APP-E1_ED_AcD eluted already at lower NaCl concentrationsTable 2
Effect of the ED_AcD on the heparin induced dimerization of the E1 domain.
Sample Theoret. MW
(kDa) of a
monomerb
Absolute MW
determined by
SLS (kDa)
APP-Ectoa 71 72 ± 5.8
APP-Ecto + Clivarin 75 77 ± 5.5
APP-E1_ED_AcDa 33 34 ± 1.9
APP-E1_ED_AcD + Clivarin 37 37 ± 0.4
APP-E1_EDa 26 23 ± 2.5
APP-E1_ED + Clivarin 30 31 ± 2.2
a Values are taken from Coburger et al. (2013).
b The calculated theoretical values include one bound heparin chain.
Fig.4. Heparin binding of different APP-constructs. The absorption at OD280 is
shown as function of the retention volume for the following APP constructs: (1)
APP-E1_ED_AcD, which eluted at 4.70 ml which corresponds to 250 mM NaCl; (2)
APP-E1_ED, which eluted at 5.94 ml or 350 mM; (3) APP-Ecto, which eluted at
6.77 ml or 420 mM; (4) APP-E1, which eluted at 7.55 ml or 450 mM and; (5)
APP-E2, which eluted at 8.28 ml or 540 mM. The applied NaCl gradient is
indicated by the grey line.
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their overall charge, as both the ED and the AcD contain a larger
number of negatively charged amino acid residues, but heparin
binding is still possible even for the APP-E1_ED_AcD-construct.
The entire ectodomain (APP-Ecto) showed as expected a binding
strength to the heparin column in-between the strongly binding
APP-E2 and the weakly binding APP-E1_ED_AcD. As heparin
binding is reduced but not completely abolished for the
dimerization-deﬁcient APP-constructs, we next analyzed their
potential for self-dimerization at high protein-concentrations.(a)
(c)
Fig.5. Self-dimerization experiments using different APP-constructs. DLS-derived appare
APP-E1_ED, (b) APP-E1_ED_AcD, (c) APP-ED_AcD_E2 and (d) APP-Ecto. The bars represen
indicated.3.6. The ED_AcD interacts with the E1-domain to interfere with its
dimerization
As observed for the isolated APP-E1 and APP-E2 preparations
(Fig. 2), the APP-E1_ED construct showed a roughly twofold
increase in apparent MW in our DLS studies upon increasing its
concentration from 0.6 to 10 mg/ml (Fig. 5a). Thus, in contrast to
the heparin induced dimerization, a concentration dependent
self-dimerization could be observed for APP-E1_ED. In contrast,
the longer construct APP-E1_ED_AcD did not show self-dimeriza-
tion at high protein concentration (Fig. 5b). All MWs determined
by DLS were basically identical within their experimental error
and within the tested concentration range of 0.6–10.0 mg/ml. Thus,
the potential to show self-dimerization at high protein concentra-
tions and the heparin-induced dimerization at low protein concen-
tration seems to be correlated for the E1-containing protein
constructs in a way that depends on the presence of the section
between E1 and E2. We next asked, whether the presence of the
ED_AcD might also inﬂuence the dimerization potential of E2. We
thus performed the DLS-based self-dimerization experiments using
constructs comprising only the ED, the AcD and the E2-domain
(Fig. 5c) and for the entire ectodomain (Fig. 5d). Interestingly, both
constructs show self-dimerization at high protein concentration as
observed for the isolated E2. The plain presence of the ED_AcD does
hence not interfere with the heparin-independent dimerization of
E2, as one would e.g. expect for a plain electrostatic effect. We thus
conclude that the ED_AcD speciﬁcally interferes with the
dimerization potential of the E1 domain of APP.4. Discussion
In addition to its role in AD, many physiological functions are
described for APP. Interestingly, many of them are inﬂuenced by(b)
(d)
nt MW as function of the protein concentration ranging from 0.6 to 10 mg/ml for (a)
t the mean values of three independent measurements and the standard deviation is
Fig.6. Model of APP dimerization. The dimerization of the APP protein is initiated
by heparin-induced dimerization of the E1 domain. Additionally, the E2 domain is
able to dimerize at lower afﬁnity and depending on its effective local concentration
as is the TM-segment of APP. (a) If both APP molecules are located at the same cell
membrane, the heparin-induced dimerization of the E1 domain will lead to a local
increase of E2 concentration and therefore to dimerization of this entity and
possibly also of the TM-segment. In our experiments the ED_AcD region, connecting
E1 and E2, prevented dimerization which could be due to conformational changes
or due to changes in heparin binding. (b) If two APP molecules are located at
different cell membranes the heparin-induced dimerization of E1 can connect the
two cells and APP would function as a cell–cell-adhesion molecule.
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the protein were described to dimerize. Employing DLS measure-
ments at different protein concentrations we could show that both,
the E1 and also the E2 domain of APP are able to self-dimerize with
low afﬁnity. The concentration-dependent self-dimerization has
been described for the E2 domain of APLP1 before. Lee and cowork-
ers report a dissociation constant for APLP1-E2 of about 200 lM
(Lee et al., 2011), which would correspond to an inﬂection point
of the DLS-based dimerization curve at a protein concentration of
5.3 mg/ml. This ﬁts well to our self-dimerization data obtained
for APP-E1 and for APP-E2. Thus, the E2 domains of APP and APLP1
seem to self-dimerize with similar afﬁnities, which is also compa-
rable to the self-dimerization capacity of APP-E1. Because such
high protein concentrations are typically not achieved under phys-
iological conditions, we speculated that there has to be another,
somehow inducing, event for the dimerization of APP.
Previously, we could show the heparin induced dimerization of
the APP-E1 domain and suggested a structural model of dimeriza-
tion (Dahms et al., 2010). Using the K103/106E double mutant of
the E1 domain we could now further support this model of dimer-
ization. Interestingly both, the self-dimerization of APP-E1 at high
protein concentration and the heparin-induced dimerization of E1
are diminished by the same mutations. Previous data from Kaden
et al. also showed that loss of the disulﬁde bond within the loop
encompassing cysteines 98 and 105 and the addition of a peptide
comprising exactly this loop-region of APP inhibit dimerization of
APP (Kaden et al., 2008). Thus, the site of E1-based self- and hepa-
rin-induced dimerization should be at similar regions of the E1
domain or even identical (see also below).
Also for the E2 domain of APLP1, heparin induced dimerization
has been described and it was suggested for APP-E2 (Lee et al.,
2011). Expecting hence a similar behavior to APP-E1 we tested
the short chain heparin preparation Clivarin (4 kDa/11 sugar
rings). Our results showed, however, only binding, but no dimer-
ization. We hence also tested the sc-203075 heparin from Santa-
Cruz, which was used by Lee et al. as well as two additional
heparin preparations of different length. As not all manufacturers
supplied the average MW for their heparin preparations and in
order not to rely on external determinations, we measured the
respective values. Interestingly, we determined the sc-203075
heparin from SantaCruz to be 15 kDa (44 sugar rings) in size
and thus to be signiﬁcantly larger than described before. This size
is large enough that two E2 molecules could bind independently to
the heparin chain without forming any direct protein–protein-
interactions. We next compared the absolute MW for mixtures of
APP-E2 and heparin preparations of different length and found that
heparin-bridged dimeric E2 moieties are only formed when the
heparin chain was long enough to enable two E2-molecules to bind
as independent entities, without need for a direct protein–protein-
contact.
Summarizing this, we could show that the E1 domain is able to
self-dimerize at higher protein concentrations, which corresponds
to a low-afﬁnity contact. This dimerization can be induced also at
low protein concentration by heparin binding. In contrast to this,
the E2 domain does only self-dimerize at high protein concentra-
tions. It binds to heparin, but the addition of short-chain heparin
does not result in its dimerization. This basically means that the
dimerization of the APP-ectodomain is energetically mainly driven
by its E1 but not by its E2 domain. Interestingly, the dimensions of
the dimer interfaces of the three described interaction sites are
quite similar (E1: 618 Å2 PDB-ID: 3KTM (Dahms et al., 2010),
E2: 740 Å2 PDB-ID: 3NYJ (Lee et al., 2011) and TM: 630 Å2
PDB-ID: 2LOH (Nadezhdin et al., 2012) as determined with the
PISA sever at http://www.ebi.ac.uk/msd-srv/prot_int) and no sig-
niﬁcant or reliable interaction energy can be determined (DG val-
ues of 2.4 kcal/mol for E1, 13.3 kcal/mol for E2 and17.4 kcal/mol for the TM) (Krissinel, 2010). These structural data
ﬁt very well to the observed weak interaction of the sole protein
contacts and might explain why the additional stabilization of
the dimeric contact by heparin is needed. Our results also nicely
ﬁt to previous observations of Soba and coworkers who found an
E1-based dimerization in co-immunoprecipitation experiments
(Soba et al., 2005). Furthermore, the data of Kaden et al., who did
see a functional dimerization of APP via its E1 domain but differ-
ences in dimerization between APP and APLP1 (Kaden et al.,
2009) are well in agreement with the results observed herein.
Surprisingly, APP-constructs containing the ED and/or AcD
(APP-E1_ED_AcD, APP-E1_ED and APP-Ecto) did not dimerize upon
their incubation with short chain heparin. Additionally, also self-
dimerization of E1 was inhibited by the ED_AcD. There must be a
currently unknown, but speciﬁc interaction between the E1
domain and the section between E1 and E2 (ED_AcD) that causes
this loss of dimerization potential. A plain electrostatic effect of
the ED_AcD would also affect the self-dimerization of E2, which
was not observed for the APP-ED_AcD_E2 construct. Whereas
dimerization of the E1 domain is inhibited by the ED_AcD, heparin
binding still seems to be possible. The APP-E1_ED_AcD construct
binds to the heparin column, although with much reduced afﬁnity
as compared to the E1 domain alone.
These results suggest a regulatory function of the ED_AcD on
APP-dimerization. Further discussion requires a much more
detailed analysis of the interaction between the ED_AcD and E1.
One has to consider that for example posttranslational modiﬁca-
tions (Klatt et al., 2013; Perdivara et al., 2009; Walter et al.,
1997), their species-speciﬁc differences or other binding proteins,
like glypican 1 (Williamson et al., 1996), will probably affect the
regulatory function of the section between E1 and E2. This might
also explain why we did not see dimerization of the entire ectodo-
main of APP, which has been reported in cell-culture experiments
or using Pichia pastoris expressed protein (Gralle et al., 2006; Soba
et al., 2005). Another explanation for observed dissimilarities
might be the use of e.g. heparin preparations of different length,
36 S. Hoefgen et al. / Journal of Structural Biology 187 (2014) 30–37diverging APP-constructs and/or alterations in the experimental
design.
Based on our results, we developed the following functional
model of APP-dimerization: if two APP molecules are located at
the same cell membrane, heparin (or physiologically probably
more relevant the heparansulfateproteoglycans (HSPG’s) that are
a component of the extracellular matrix (ECM)) could bind to the
APP ectodomain and induce thereby the initial dimerization of
the E1 domain. Subsequently, this would lead to a local increase
in the effective E2 domain concentration and therefore induce
the low-afﬁnity self-dimerization of E2 and possibly also that of
the TM (Fig. 6a). As long as the dimerization inducing ligand (here
heparin/HSPG’s, but one could also consider other polyanions) can
get internalized together with APP, such a dimerization can not
only occur at the cell surface but also intracellular. If no polyanion
is present, only the weaker contacts based on self-dimerization can
be formed, which is of course always possible. This dimerization
could also regulate the proteolytic cleavage of APP and therefore
the generation of the neurotoxic Ab-peptide and the soluble forms
of APP. It is e.g. known that different proteins bind to the AICD
forming a transcriptional active complex (Cao and Sudhof, 2001,
2004). Dimerization of APP could in this way also inﬂuence the
transcription of APP target genes. This interaction mode could also
be relevant for the APP-based attachment of cells to the ECM
(Beher et al., 1996; Cáceres and Brandan, 1997). In a second case,
two APP molecules could be located at membranes of different
cells. Here, dimerization would be mediated only by the E1
domain, linking both cells to one another (Fig. 6b). Such a
trans-dimer is not compatible with endocytosis and internalization
without prior disruption of the dimer. Indeed a function as a
cell–cell-adhesion protein has been described for APP (Soba et al.,
2005) and Baumkötter et al. showed that APP could function as a
synaptic cell adhesion molecule (SAM), connecting two neurons
(Baumkotter et al., 2012). If these two membrane patches originate
from the same membrane instead of different cells, this conﬁgura-
tion could also offer a molecular explanation how APP could be
involved in the formation and in budding off of vesicles.
Summarizing, we could show that the dimerization of the APP
ectodomain is mainly mediated by the heparin-induced dimeriza-
tion of the E1 domain, which leads to an effective local increase in
the concentration of its E2 domain and TM-helix and therefore to a
concentration dependent dimerization of the latter dimeric con-
tacts. Dimerization of APP is regulated by the ED_AcD.
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